Finally, some individuals in the imaging cohort may have subtle neuropathological comorbidities that contribute to cognitive impairment, qualifying an amyloid PET positive case with low AD neuropathological change (transentorhinal versus limbic stages of tau pathology) for inclusion in this study. Here, MAPT is linked to Cognitive impairment.